Steven J. Romano - 02 Jan 2025 Form 3 Insider Report for Silence Therapeutics plc (SLN)

Role
EVP and Chief R&D Officer
Signature
/s/ Rhonda Hellums, Attorney-in-Fact
Issuer symbol
SLN
Transactions as of
02 Jan 2025
Net transactions value
$0
Form type
3
Filing time
02 Jan 2025, 16:26:31 UTC
Previous filing
18 Sep 2024
Next filing
22 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SLN Ordinary Shares 12,993 02 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SLN Employee Share Option (Right to Buy) 02 Jan 2025 Ordinary Shares 48,000 $7.87 Direct F1
holding SLN Employee Share Option (Right to Buy) 02 Jan 2025 Ordinary Shares 300,000 $2.07 Direct F2
holding SLN Employee Share Option (Right to Buy) 02 Jan 2025 Ordinary Shares 48,000 $5.13 Direct F3
holding SLN Employee Share Option (Right to Buy) 02 Jan 2025 Ordinary Shares 450,000 $3.27 Direct F4
holding SLN Employee Share Option (Right to Buy) 02 Jan 2025 Ordinary Shares 225,000 $5.90 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vested or shall vest in equal monthly installments over a three-year period measured from one month following January 6, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
F2 One fourth (1/4th) of the shares subject to the option vested on April 1, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.
F3 This option vested or shall vest in equal monthly installments over a three-year period measured from one month following September 14, 2023, subject to the Reporting Person's continuous service as of the applicable vesting date.
F4 This option vested or shall vest in equal monthly installments over a four-year period measured from one month following October 1, 2023, subject to the Reporting Person's continuous service as of the applicable vesting date.
F5 One fourth (1/4th) of the shares subject to the option shall vest on January 4, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.